title: 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial.
authors: B
authors: B
authors: Young
authors: T
authors: T
authors: Vanig
authors: E
authors: E
authors: DeJesus
authors: T
authors: T
authors: Hawkins
authors: M
authors: M
authors: St Clair
authors: B
authors: B
authors: Stancil
authors: B
authors: B
authors: Ha
authors: Shield Study Team
mesh_terms: D015224:Dideoxynucleosides / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D011760:Pyrrolidinones / Q000008:administration & dosage*
chemical_list: D015224:Dideoxynucleosides; D011760:Pyrrolidinones; D019259:Lamivudine